We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Experience with Amphotericin B for the Treatment of Systemic Mycoses

AMA Arch Intern Med. 1958;102(6):960-976. doi:10.1001/archinte.1958.00260230106014.
Text Size: A A A
Published online


Amphotericin B is an antibiotic produced by a species of Streptomyces. It appears to have no important antibacterial properties, but possesses highly significant activity against those yeast-like fungi which produce deep mycotic infection in man. Table 1 contains the in vitro sensitivities of the major producers of deep mycotic infection in man as determined by various investigators.1-3 Our own findings, on Sabouraud's dextrose agar at pH 7, are indicated in the Table.

Studies in experimental animals2,3 have indicated a good correlation between in vivo effectiveness and in vitro sensitivity to amphotericin B. Animal toxicity studies carried out by the Squibb Institute for Medical Research indicated that amphotericin B had a therapeutic index sufficient to justify clinical trial in human mycotic infections. Several reports 4-6 of its use in histoplasmosis and cryptococcosis have already appeared in the American literature.

Routes of Administration and Toxicity  The insolubility of crystalline or


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.